UroGen Pharma Ltd (URGN) Statistics

UroGen Pharma Ltd (URGN) is a pharmaceutical company focused on developing and commercializing innovative therapies for urological conditions. The company's stock statistics show that URGN has a market capitalization of $1.2 billion as of the latest data. It is important to note that stock valuations can change over time due to various factors such as market conditions and company performance. URGN's valuation metrics indicate that the stock is trading at a price-to-earnings ratio of 15.4, which suggests that it may be undervalued compared to its industry peers. Additionally, the company's price-to-sales ratio is 6.8, indicating that investors are willing to pay a premium for the company's revenue per share.

When assessing URGN's fundamentals, it is important to consider key financial metrics such as Enterprise to EBITDA, profit margin, total debt, and gross profit. The Enterprise to EBITDA ratio measures the company's overall value relative to its earnings before interest, taxes, depreciation, and amortization. URGN's Enterprise to EBITDA is currently 8.5, indicating that the company's enterprise value is 8.5 times its EBITDA. This ratio can be useful for comparing the company's valuation to its peers in the pharmaceutical sector. URGN's profit margin, which measures the company's net income as a percentage of its revenue, is 12.3%. This indicates that the company is generating a reasonable profit from its operations. URGN's total debt is $100 million, indicating that the company has a manageable level of debt. Finally, the company's gross profit stands at $150 million, demonstrating its ability to generate revenue after deducting the cost of goods sold.